Pages that link to "Q43874206"

The following pages link to The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity (Q43874206):

Displaying 29 items.

• Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival (Q34502648) (← links)
• Addressing phenoconversion: the Achilles' heel of personalized medicine (Q35023701) (← links)
• Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling (Q35827538) (← links)
• Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity (Q35922156) (← links)
• AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. (Q36481089) (← links)
• Pharmacogenomics: the promise of personalized medicine for CNS disorders. (Q37272534) (← links)
• DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping (Q37377361) (← links)
• Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity (Q37380190) (← links)
• Implementation of CYP2D6 genotyping in psychiatry (Q37538787) (← links)
• Complexities of CYP2D6 gene analysis and interpretation (Q38154914) (← links)
• Cytochrome P450 pharmacogenetics in African populations: implications for public health (Q38192688) (← links)
• Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing (Q39282325) (← links)
• Human pharmacogenomics: the development of a science (Q41985354) (← links)
• Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. (Q43244977) (← links)
• The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations (Q44188968) (← links)
• Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. (Q45151691) (← links)
• CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing (Q46564749) (← links)
• The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans (Q46765977) (← links)
• The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype (Q46922848) (← links)
• Precision medicine: does ethnicity information complement genotype-based prescribing decisions? (Q47566249) (← links)
• Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa. (Q52348869) (← links)
• CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. (Q54605695) (← links)
• Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study. (Q54766895) (← links)
• Disease burden and the role of pharmacogenomics in African populations. (Q54935902) (← links)
• Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo (Q56828628) (← links)
• CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort (Q58698638) (← links)
• Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy (Q80997948) (← links)
• Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort (Q86561736) (← links)
• CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels (Q90302004) (← links)